Resources and Education for Operationalizing Bispecifics

Key Takeaways

• Institutions can utilize specialized training programs and partnerships with biotech firms to address bispecific antibody challenges.
• Comprehensive regulatory guidance is crucial for navigating the complex approval processes associated with bispecific antibodies.
• Stakeholders need education on the unique pharmacodynamics and clinical implementation of bispecific antibodies.
• Strategies for managing potential adverse effects are essential for successful integration into treatment protocols.